Gsa Capital Partners LLP Mersana Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 271,774 shares of MRSN stock, worth $195,677. This represents 0.04% of its overall portfolio holdings.
Number of Shares
271,774
Previous 57,960
368.9%
Holding current value
$195,677
Previous $116,000
343.1%
% of portfolio
0.04%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding MRSN
# of Institutions
121Shares Held
116MCall Options Held
233KPut Options Held
457K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$13.9 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$8.69 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$8.16 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$6.24 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$6.04 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $70M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...